* Corresponding authors

^a Nano-Oncology and Translational Therapeutics Unit, Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, A Coruña, Spain
E-mail: sainza.lores@gmail.com, maria.cascallarc@gmail.com, maria.fuente.freire@sergas.es
Tel: +34-981-955-706

^b Universidade de Santiago de Compostela (USC), Praza do Obradoiro, s/n, Santiago de Compostela, A Coruña, Spain

^c Translational Cancer Research Laboratory, Department of Biochemistry, Autonomous University of Madrid, School of Medicine, “Alberto Sols” Biomedical Research Institute CSIC-UAM, IdiPaz, Arturo Duperier 4, Madrid, Spain
E-mail: mgamez@iib.uam.es, cramos@iib.uam.es, gmoreno@iib.uam.es

^d Biomedical Cancer Research Network (CIBERONC), 28029 Madrid, Spain

^e Roche-CHUS Join Unit. Translational Medical Oncology Group (ONCOMET), Health Research Institute of Santiago de Compostela (IDIS), Travesía da Choupana s/n, Santiago de Compostela, A Coruña, Spain
E-mail: felurh@gmail.com, sandraalijasperez@gmail.com, rafa.lopez.lopez@gmail.com, Roberto.Pineiro.Cid@sergas.es

^f MD Anderson International Foundation, Gómez Hemans s/n, 28033 Madrid, Spain

^g DIVERSA Technologies SL, Edificio Emprendia, Universidade de Santiago de Compostela, Campus Vida s/n, 15782 Santiago de Compostela, Spain